The results showed that this treatment reduced the relapse rate due to the GvL effect, which was generated by the increased numbers of NK and CD8+ T cells, and controlled the progression of GvHD due to the increased numbers of Treg cells. The gene discussed is CD8A; the disease is graft versus host disease.